Regulatory Peptides in Renal Failure: Effects and Possible Pathophysiological Role

Feldman H.A. , Singer I. Endocrinology and metabolism in uremia and dialysis: a clinical review. Medicine 1974; 54: 345.

Berman L.B. Urine isn't everything. JAMA 1975; 231: 978.

Hansky J. Effect of renal failure on gastrointestinal hormones. World J Surg 1979; 3: 463–7.

Reinecke M. , Forssmann W.G. Neuropeptide (neuropeptide Y, neurotensin, vasoactive intestinal polypeptide, substance P, calcitonin gene-related peptide, somatostatin) immunohistochemistry and ultrastructure of renal nerves. Histochemistry 1988; 89: 1–9.

Woods R.L. Contribution of the kidney to metabolic clearance of atrial natriuretic peptide. Am J Physiol 1988; 255: E934–41.

EI Munshid H.A. , Hoist J.J. , Lundquist I. Role of the kidneys in elimination of glucagon, insulin, secretin and somatostatin in the rat. Acta Physiol Scand 1983; 117: 27–31.

Maack T. , Almeida F.A. , Suzuki M. , Nussenzveig D.R. Clearance receptors of atrial natriuretic factor. Contrib Nephrol 1988; 68: 58–65.

Sonnenberg H. Renal effects of atrial natriuretic factor. ISI Atlas of Science: Pharmacology 1988; 1: 171–4.

Brenner B.M. , Laragh J.H. , eds. Biologically active atrial peptides. American Society of Hypertension Symposium Series. Raven Press: New York, 1987; vol. 1.

Brenner B.M. , Laragh J.H. , eds. Advances in atrial peptide research. American Society of Hypertension Symposium Series. Raven Press: New York, 1988; vol. 2.

Haberich F.J. Osmoreception in the portal circulation. Federation Proc 1968; 27: 1137–41.

Passo S.S. , Thornborough J.R. , Rothballer A.B. Hepatic receptors in control of sodium excretion in anesthetized cats. Am J Physiol 1973; 224: 373–5.

Leanne R.J. , Peart W.S. , Carey R.M. , Shaw J. A comparison of natriuresis after oral and intravenous sodium loading in sodium-depleted rabbits: evidence for gastrointestinal or portal monitor of sodium intake. Clin Sci and Molec Med 1975; 49: 433–6.

Ebeid A.M. , Escorru J. , Soeters P.B. , Murray P. , Fischer J.E. Hepatic inactivation of vasoactive intestinal peptide in man and dog. Ann Surg 1977; 188: 28–33.

Duggan K.A. , MacDonald G.J. Vasoactive intestinal peptide; a direct renal natriuretic substance. Clin Science 1987; 72: 195–200.

Myiata A. , Kangawa K. , Toshimori T. , Hatoh T. , Matsuo H. Molecular forms of atrial natriuretic polypeptides in mammalian tissues and plasma. Bioch Biophys Res Comm 1985; 129: 248–55.

Walker R.G. , Swainson C.P. , Yandle T.G. , Nicholls M.G. , Espiner E.A. Exaggerated responsiveness of immunoreactive atrial natriuretic peptide to saline infusion in chronic renal failure. Clin Science 1987; 72: 19–24.

Sagnella G.A. , Markandu H.D. , Shore A.C. , MacGregor G.A. Raised circulating levels of atrial natriuretic peptides in essential hypertension. Lancet 1986; 1: 179–81.

Larochelle P. , Béroiniade V. , Gutkowska J. Influence of hemodialysis on the plasma levels of the atrial natriuretic factor in chronic renal failure. Clin Invest Med 1987; 10 350–4.

Yamamoto Y. , Higa T. , Kitamura K. , Tanaka K. , Kangawa K. , Matsuo H. Plasma concentration of human atrial natriuretic polypeptide in patients with impared renal function. Clin Nephrol 1987; 27: 84–6.

Larochelle P. , Cusson J.R. , Gutkowska J. Plasma atrial natriuretic factor concentrations in essential and renovascular hypertension. Br Med J 1987; 294: 1249–53.

Eisenhauer T. , Talartschik J. , Sheler F. Detection of fluid overload by plasma concentration of human atrial natriuretic peptide (h-ANP) in patients with renal failure. Klin Wochenschr 1986; 64(Suppl VI): 68–72.

Hartter E. , Pacher R. , Frass M. , Wolosbczik W. , Leihtner C. Plasma levels of atrial natriuretic peptide (ANP) in volume expanded patients: Response to fluid removal by continuous pump driven hemofiltration. Klin Who-chenschr 1986; 64(Suppl VI): 112–4.

Lang R.E. , Unger T. , Ganten D. Atrial natriuretic peptide: a new factor in blood pressure control. J Hypertens 1987; 5: 255–71.

Napier M.A. , Vandeln R.L. , Albers-Schömberg G. Specific membrane receptors for atrial natriuretic factor in renal and vascular tissues. Proc NAS 1984; 81: 5946–50.

Bidiville J. , Waber G. , Porchet M. Hemodynamic, renal and endocrine effects of 4-H infusions of human atrial natriuretic peptide in normal volunteers. Fundam in Pharmacol 1988; 2: 413–29.

Maack T. , Marion D.N. , Camargo M.J.F. Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function and the renin-aldosterone system in dogs. Am J Med 1984; 77: 1069–75.

Maack T. , Kleiner H.D. Renal, cardiovascular effects of atrial natriuretic factor. Biochem Pharmacol 1986; 35: 2057–64.

Harris P.J. , Thomas D. , Morgan T.O. Atrial natriuretic peptide inhibits angiotensin - stimulated proximal tubular sodium and water reabsorption. Nature 1987; 326: 697–8.

Bourgoignie J.J. , Gavellas G. , Hwang K.H. Renal effects of atrial natriuretic factor in primates. Am J Physiol 1986; 251: F1049–54.

Weidmann P. , Heiser L. , Gnadinger M.P. Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest 1986; 77: 734–42.

Murthy K. , Thibault G. , Garcia R. , Gutkowska T.J. , Genest J. , Cantin M. Degradation of atrial natriuretic factor in the rat. Biochem J 1986; 240: 461–9.

Luft F.C. , Lang R.E. , Arnoff G.R. Atriopeptin III kinetics and pharmacodynamics in normal and anephric rats. J Pharmacol Exp Ther 1986; 236: 416–8.

Biollaz J. , Callahan L.T. , Nussberger J. Pharmacokinetics of synthetic atrial natriuretic peptide in normal men. Clin Pharm Ther 1987; 671–7.

Gnaedinger M.P. , Lamg R.E. , Hasler L. , Uehlinger D.E. , Shaw S. , Weidmann P. Plasma kinetics of synthetic alpha human atrial natriuretic peptide in man. Miner Electrolyte Metab 1986; 12: 371–4.

Katsube N. , Schwartz D. , Needleman P. Atriopeptin turnover: quantitative relationship between in vivo changes in plasma levels and atrial content. J Pharm Exp Ther 1986; 239: 474–9.

Crozier I.G. , Nicholls G. , Ikram H. , Espiner E.A. , Yandle T.G. , Jans S. Atrial natriuretic peptide in humans. Production and clearance by various tissues. Hypertension Dallas 8, 1986; Suppl II: 11–5.

Stephenson S.L. , Kenny A.J. The hydrolysis of a/human, natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J 1987; 243: 183–7.

Ando K. , Umetani N. , Kurosawa T. , Takeda S. , Katoh Y. , Marumo F. Atrial natriuretic peptide in human urine. Klin Wochenschr 1988; 66: 768–72.

Predel H-G , Kipnowski J. , Meyer-Lehnert H. , Arendt R.M. , Kramer H.J. Human atrial natriuretic peptide in non-dialyzed patients with chronic renal failure. Clin Nephrol 1989; 31: 150–5.

Yamamoto Y. , Higa T. , Kitamura K. , Tanaka K. , Kengawa K. , Matsuo H. Plasma concentration of atrial natriuretic polypeptide in chronic hemodialysis patients. Regulatory Peptides Suppl 1985; 4: 110–3.

Rascher W. , Tulassay T. , Lang R.E. Atrial natriuretic peptide in plasma of volume-overloaded children with chronic renal failure. Lancet 1985; ii: 303–5.

Hodsman G.P. , Jackson B. , Debrevi L.M. , Ogawa K. , Johnston C.I. Atrial natriuretic factor in chronic renal failure: Studies in man and the rat. Clin Exp Pharmacol & Physiol 1987; 14: 247–51.

Hasegawa K. , Matsushita Y. , Inoue T. , Morii H. , Ishibashi M. , Yamaji T. Plasma levels of atrial natriuretic peptide in patients with chronic renal failure. J Clin Endocrinol Metab 1986; 63: 819–22.

Predel H.G. , Backer A. , Kipnowsky J. , Dusing R. , Kramer H.J. Relationship of plasma concentrations of human atrial natriuretic peptide (alpha-hANP) to renal functions and blood pressure in progressive chronic renal failure. In: The American Society of Hypertension. Second World Congress on Biological Active Atrial Peptides, 1987; 221–3.

Predel H-G , Kipnowski J. , Bäcker A. Erhöhte plasmaspiegel und heterogenität von humanem atrialem natriuretischen peptid bei patienten mit progressiven chronischen nierenversagen. Zeitschrift fur Kardiologie 1988; 77(Suppl 2): 65–71.

Horky K. , Widimsky J. Jr. , Sramkova J. , Lachmanova J. Atrial natriuretic peptide concentration and natriuretic hormone activity in plasma of patients with chronic renal failure. Horm Metab Res 1988; 20: 709–12.

Rascher W. , Bald M. , Kroner F. , Tulassay T. , Muller-Wiefel D.E. Klinische wertigheit der messung des atrialen natriuretischen peptids im plasma von kindern mit chronischer niereninsuffizienz. Zeischrift fur Kardiologie 1988; 77(Suppl 2): 61–4.

Andersson U. , Sylvén C. , Lindvall K. , Theodorsson E. , Norée L-O . Cardiac function and cardiovascular hormone balance during hemodialysis with special reference to atrial natriuretic peptide. Clin Nephrol 1988; 30: 303–7.

Saxenhofer H. , Gnädinger M.P. , Weidmann P. Plasma levels and dialysance of atrial natriuretic peptide in terminal renal failure. Kidney Int 1987; 32: 554–61.

Deray G. , Maistre G. , Basset J.Y. Plasma levels of atrial natriuretic peptide in chronically dialyzed patients. Kidney Int 1988; 34(Suppl 25): S86–8.

Sanaka T. , Tsuchiya K. , Nitta K. , Sone M. , Sugino N. Role of atrial natriuretic peptide in experimental renal failure. Japanese Circulation Journal 1988; 52: 1441–5.

Anderson J.V. , Raine A.E.G. , Proudler A. , Bloom S.R. Effect of hemodialysis on plasma concentration of atrial natriuretic peptide in adult patients with chronic renal failure. J Endocrinol 1986; 110: 193–6.

Zoccali M. , Ciccarelli F. , Mallamaci F. Effect of ultrafiltration on plasma concentration of atrial natriuretic peptide in hemodialysis patients. Nephrol Dial Transplant 1986; 1: 188–91.

Talartschik J. , Eisenhauer T. , Voth E. , Sold G. , Scheler F. Ist der plasma-ANP-spiegel ein index fur die volumenexpansion bei dialysepatienten. Zeischrift fur Kardiologie 1988; 77(Suppl 2): 72–7.

Kojima S. , Inoue I. , Hirata Y. Plasma concentrations of immunoreactive atrial natriuretic polypeptide in patients on hemodialysis. Nephron 1987; 46: 45–8.

Peterson C. , Madsen B. , Perlman A. , Chan A.Y.M. , Myers B. Atrial natriuretic peptide and the renal response to hypervolemia in nephrotic humans. Kidney Int 1988; 34: 825–31.

Koepe J.P. , Dibona G.F. Blunted natriuresis to atrial natriuretic peptide in chronic sodium-retaining disorders. Am J Physiol 1987; 252: F865–71.

Perico N. , Delani F. , Lupini C. , Remuzzi G. Renal response to atrial peptides is reduced in experimental nephrosis. Am J Physiol 1987; 252: F654–60.

Tulassay T. , Rascher W. , Lang R.E. , Seyberth H.W. , Schärer K. Atrial natriuretic peptide and other vasoactive hormones in nephrotic syndrome. Kidney Int 1987; 31: 1391–5.

Burnier M. , Mooser V. , Wauters J.P. Bolus injection of synthetic atrial natriuretic peptide in patients with chronic renal failure or nephrotic syndrome. J Cardiovasc Pharm 1989; 13: 682–90.

Doorenbos C.J. , Daha M.R. , Van Brummelen P. Correlates of plasma atrial natriuretic peptide levels in renal transplant recipients. Clin Nephrol 1989; 31: 146–9.

Sterzel R.B. , Luft F.C. , Lang R.E. , Gamten D. Effects of atrial natriuretic factor in rats with renal insufficiency. J Lab Clin Med 1987; 110: 63–9.

Gianello P. , Poelaert D. , Ramboux A. Beneficial effect of atrial natriuretic factor on ischemically injured kidneys in the rat. Transplantation 1988; 45: 860–3.

Heidbreder E. , Schaffaerhans K. , Schramm D. , Götz R. , Heidland A. Toxic renal failure in the rat: beneficial effect of atrial natriuretic factor. Klin Wochenschr 1986; 64(Suppl VI): 78–82.

Cole B.R. , Schwartz D. , Manning P.T. , Katsube N.C. , Needleman P. Atriopeptins: circulating volume regulatory hormones with potential therapeutic role in chronic renal failure. J Hypertens 1986; 4(Suppl 2): S13–6.

Cole B.R. , Kuhnline M.A. , Needleman P. Atriopeptin III, a potent natriuretic, diuretic, and hypotensive agent in rats with chronic renal failure. J Clin Invest 1986; 76: 2413–5.

Suda S. , Weidmann P. , Saxenhofer H. , Cottier C. , Shaw S. , Ferrier C. Atrial natriuretic factor in mild to moderate chronic renal failure. Hypertension 1988; 11: 483–90.

Jancso N. , Jancso-Gabor A. , Szolcsanyi J. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol 1967; 31: 138–51.

Pernow B. Substance P. Pharmacological Reviews 1983; 35: 85–141.

Maggi C.A. , Meli A. The sensory-efferent function of capsaicin-sensitive sensory neurons. Gen Pharmac 1988; 19: 1–43.

Holzer P. Local effector functions of capsaicin sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 1988; 24: 739–68.

Ferguson M. , Bell C. Substance P-immunoreactive nerves in the rat kidney. Neurosci Lett 1985; 60: 183–8.

Ferguson M. , Ryan G.B. , Bell C. Localization of sympathetic and sensory neurons innervating the rat kidney. J Auton Nerv Syst 1986; 16: 279–88.

Ferguson M. , Bell C. Ultrastructural localization and characterization of sensory nerves in the rat kidney. J Comp Neurol 1988; 274: 9–16.

Åström A. , Crafoord J. Afferent activity recorded in the kidney nerves of rats. Acta Physiol Scand 1967; 70: 10–5.

Moss N.G. Renal function and renal afferent and efferent nerve activity. Am J Physiol 1982; 243: F425–33.

Kopp U.C. , Olson L.A. , DiBona G.F. Renorenal reflex responses to mechano-and chemoreceptor stimulation in the dog and rat. Am J Physiol 1984; 246: F67–77.

Goodman E.C. , Iversen L.L. Calcitonin gene-related peptide. Life Sci 1986; 38: 2169–78.

Dockray G.J. Calcitonin gene-related peptide. ISI Atlas of Science Pharmacology 1988; 1: 40–5.

Zaidi M. , Bevis P.J.R. , Abeyasekera G. The origin of circulating calcitonin gene-related peptide in the rat. J Endocr 1986; 110: 185–90.

Emson P. , Zaidi M. Further evidence for the origin of circulating calcitonin gene-related peptide in the rat. J Physiol 1989; 412: 297–308.

Breimer L.H. , McIntyre I. , Zaidi M. Peptides from the calcitonin genes: molecular genetics, structure and function. Biochem J 1988; 255: 377–90.

McEvan J.R. , Benjamin N. , Larkin S. , Fuller R.W. , Dollery C.T. , McIntyre I. Vasodilatation by calcitonin gene-related peptide and by substance P: a comparison of their effects on resistence and capacitance vessels of human forearms. Circulation 1988; 77: 1072–80.

Gennari C. , Fischer J.A. Cardiovascular action of calcitonin gene-related peptide in humans. Calcif Tissue Int 1985; 37: 581–4.

Gamse R. , Saria A. Potentiation of tachykinin-induced plasma protein extravasation by calcitonin gene-relate peptide. Eur J Pharmacol 1985; 114: 61–6.

Franco-Creceda A. , Lundberg J.M. Calcitonin gene-related peptide (CGRP) and capsaicin-induced stimulation of heart contractile rate and force. Naunyn-Schmiedeberg's Arch Pharmacol 1985; 331: 146–51.

Xu D. , Wang X. , Wang J-P . Calcitonin gene-related peptide (CGRP) in normotensive and spontaneously hypertensive rats. Peptides 1989; 10: 309–12.

Hvarfner A. , Bergström R. , Mörlin C. , Theodorsson E. , Ljunghall S. The calcitonin gene-related peptide (CGRP) response to intravenous calcium is related to blood pressure. Acta Physiol Scand 1988; 132: 439–40.

Villareal D. , Freeman R.H. , Verburg K.M. , Brands M.V. Renal hemodynamic response to intrarenal infusion of calcitonin gene-related peptide in dogs. Peptides 1988; 9: 1129–35.

Villareal D. , Freeman R.H. , Verburg K.M. , Brands M.W. Effects of calcitonin gene-related peptide on renal blood flow in the rat. Proc Soc Exp Biol Med 1988; 188: 316–22.

Gennari C. , Nami R. , Agnusdei D. , Biamchini C. , Pavese G. Acute cardiovascular and renal effects of human calcitonin gene-related peptide. Am J Hypertens 1989; 2: 45S–9.

Santicicoli P. , Maggi C.A. , Gepetti P. , Del Bianco E. , Theodorsson E. , Meli A. Release of calcitonin gene-related peptide-like immunoreactivity (CGRP-LI) from organs of the genitourinary tract in rats. Neurosci Lett 1988; 92: 197–201.

Hua X-Y , Theodorsson-Norheim E. , Lundberg J.M. , Kinn A.C. , Hökfelt T. , Cuello A.C. Co-localization of tachykinins and calcitonin gene-related peptide in capsaicin-sensitive afferents in relation to motility effects on the human ureter in vitro. Neuroscience 1987; 23: 693–703.

Kurtz A. , Muff R. , Lundberg J.M. Calcitonin gene-related peptide is a stimulator of renin secretion. J Clin Invest 1988; 82: 538–43.

Odar-Cederlöf I. , Theodorsson E. , Eriksson C.G. , Kjellstrand C.M. Plasma concentrations of calcitonin gene-related peptide increase during haemodialysis: relation to blood pressure. Int J Med 1989; 226: 177–82.

Gamse R. , Mroz E. , Leeman S.E. , Lembeck F. The intestine a source of immunoreactive substance P in plasma of the cat. Naunyn-Schmiedeberg's. Arch Pharmacol 1978; 305: 17–21

Hua X-Y , Lungberg J.M. , Theodorsson-Norheim E. , Brodin E. Comparison of cardiovascular and bronchoconstrictor effects of substance P, substance K and other tachykinins. Naunyn-Schmiedeberg's Arch Pharmacol 1984; 328: 196–201. Erratum 328: 3–61.

Dunér H. , Pernow B. Circulatory studies on substance P in man. Acta Physiol Scand 1960; 49: 261–6.

Gullner H-G , Campbell W.B. , Pettinger W.A. Role of substance P in water homeostasis. Life Sci 1979; 24: 2351–60.

Gullner H-G , Campbell W.B. , Pettinger W.A. Effects of substance P on renin release and renal function in anesthetized dogs. Life Sci 1979; 24: 235–46.

Stephenson S.L. , Kenny A.J. Metabolism of neuropeptides. Hydrolysis of angiotensins, bradykinins, substance P and oxytocin by pig kidney microvillar membranes. Biochem J 1987; 241: 237–47.

Inoue A. , Yanagisawa M. , Kimbura S. The human endothelin family: three structurally and pharmacologically distinct isopeptides preticted by three separate genes. Proc NAS 1989; 86: 2863–7.

Jones C.R. , Hiley C.R. , Pelton J.T. , Miller R.C. Autoradiographic localization of endothelin binding sites in kidney. Eur J Pharmacol 1989; 163: 379–82.

Koyama H. , Tabata T. , Nishzawa Y. , Inoue T. , Morii H. , Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet 1989; i: 991–2.

Webb D.J. , Cockkcroft J.R. Plasma immunoreactive endothelin in uraemia. Lancet 1989; i: 1211.

Pernow J. , Lundberg J.M. , Kaiser L. Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci 1987; 40: 47–54.

Ekblad E. , Edvinsson L. , Wahlstedt C. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept 1984; 8: 225–35.

Lundberg J.M. , Fried G. , Pernow J. , Theodorsson-Norheim E. Co-release of neuropeptide Y and catecholamines upon adrenal activation in the cat. Acta Physiol Scand 1986; 126: 231–8.

Pernow J. , Saria A. , Lundberg J.M. Mechanisms underlying pre- and post-junctional effects of neuropeptide Y in sympathetic vascular control. Acta Physiol Scand 1986; 126: 239–49.

Potter E.K. Neuropeptide Y as an autonomic neurotransmitter. Pharmac Ther 1988; 37: 251–73.

Raine A.E.G. , Allen J.M. , Ledingham J.G.G. , Bloom S.R. Clin Exper Theory and Practice 1984; A6 (10–11): 1957–60.

Allen J.M. , Raine A.E.G. , Ledingham J.G.G. , Bloom S.R. Neuropeptide Y: a novel peptide with vasoconstrictor and natriuretic activity. Clin Science 1985; 68: 373–7.

Baranowska B. , Gutkowska J. , Lemire A. , Cantin M. , Genest J. Opposite effects of neuropeptide Y (NPY and polypeptide YY (PYY) on plasma immunoreactive atrial natriuretic factor (IR-ANF) in rats. Biochem Biophys Res Comm 1987; 145: 680–5.

Tagashi K. , Moury T. , Itoi K. Increased plasma immunoreactive neuropeptide Y concentrations in pheochromocytoma and chronic renal failure. J Hypertens 1987; 5: 749–53.

Thorn S.M. , Hughes A.D. , Goldberg P. , Martin G. , Schachter M. , Sever P.S. The actions of calcitonin gene-related peptide and vasoactive intestinal peptide as vasodilators in man in vivo and in vitro. Br J Clin Pharmac 1987; 24: 139–44.

Dimaline R. , Peart W.S. , Unwin R.J. Effects of vasoactive intestinal polypeptide (VIP) on renal function in the conscious rabbit. J Physiol (Lond) 1983; 344: 379–88.

Rossa R. , Stoff J.S. , Silva P. , Epstein F.H. Tubular diuresis induced by vasoactive intestinal peptide (VIP) in the isolated perfused rat kidney. Clinical Research 1977; 25: 669A.

McGuigan J.E. Antibodies to the carboxy-terminal tetra-peptide of gastrin. Gastroenterology 1967; 53: 697–700.

Schluter K.J. , Neufeld M. , Del Pozo E. , Marback P. , Cramer H. , Kerp L. Studies in healthy human volunteers of new somatostatin analogue: SMA 201–995. 65th Annual Meeting of the Endocrine Society. San Antonio Texas, 1983; (Abstract 527).

Williams G. , Burrin J.M. , Ball J.A. , Joplin G.F. , Bloom S.R. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMA 201–995. Lancet 1986; ii: 774–8.

Fussl H.S. , Domin J. , Bloom S.R. Oral adsorption of the somatostatin analogue SMA 201–996: theoretical and practical implications. Clin Science 1987; 72: 255–57.

Lembcke B. , Creutzfeldt W. , Schleser S. , Ebert R. , Shaw C. , Koop I. Effect of the somatostatin analogue sandostatin (SMS 201–995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 1987; 36: 108–24.

Moreau J.P. , Defeudis F.V. Minireview. Pharmacological studies of somatostatin and somatostatin-analogues: therapeutic advances and perspectives. Life Sci 1987; 40: 419–37.

Schally A.V. Oncological applications of somatostatin analogues. Cancer Res 1988; 48: 6977–85.

Wynick D. , Polak J.M. , Bloom S.R. Somatostatin and its analogues in the therapy of gastrointestinal disease. Pharmac Ther 1989; 41: 353–70.

Gorden R.J. Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110: 35–50.

Lundquist G. , Gustavsson S. , Hällgren R. Plasma levels of somatostatin-like immunoreactivity. Independence of kidney function. Clin Endocrinol 1979; 10: 489–92.

Wasada T. , Inoue K. , Fujimi S. , Sako Y. , Hisatomi A. , Ibayashi H. Hypersomatostatinemia in chronic renal failure. Endocrinol Jpn 1987; 251–6.